[18F]FET
Stories
-
Telix registers Phase 3 study of [18F]FET PET in brain metastases
The study, led by Telix Pharmaceuticals (Innovations) Pty Limited, plans to enroll 381 participants and begin in December 2026. It will evaluate whether [18F]Floretyrosine PET can differentiate tumor progression from treatment-related changes in patients with brain metastases and equivocal MRI findings.